GlassScriptPhysician profile
Felix Alva Valdes
NPI 1386643195
$3,999.75
in general payments reported to CMS, 2019-2025
29 companies · $715 in 2025
The $715 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $140 · 2021: $404 · 2022: $868 · 2023: $535 · 2024: $769 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $729.53 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $567.80 | 2019-2024 | Xarelto |
| Amgen INC. | $394.27 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $346.60 | 2019-2025 | Confirm Rx, Assurity |
| Astrazeneca Pharmaceuticals LP | $274.24 | 2019-2025 | Brilinta, Wainua |
| Novartis Pharmaceuticals Corporation | $262.02 | 2019-2025 | |
| Pfizer INC. | $261.77 | 2019-2025 | |
| Shockwave Medical, INC | $235.83 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $151.17 | 2019-2025 | Camzyos |
| Boston Scientific Corporation | $122.37 | 2024 | Watchman Flx |
| Amarin Pharma, INC. | $122.03 | 2019-2021 | |
| Chiesi USA, INC. | $84.82 | 2019-2025 | Kengreal, Cleviprex |
| Sanofi-Aventis U.S. LLC | $42.96 | 2019 | |
| Medtronic Vascular, INC. | $38.92 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $38.80 | 2023-2024 | Inpefa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $37.99 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.21 | 2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $33.82 | 2024 | Arcalyst |
| Medtronic, INC. | $33.67 | 2021-2023 | Onyx Frontier |
| Novo Nordisk INC | $24.15 | 2025 | Ozempic |
| Philips North America LLC | $22.79 | 2019 | |
| Melinta Therapeutics, LLC | $21.68 | 2023 | Kimyrsa |
| Esperion Therapeutics, INC. | $19.43 | 2021 | |
| Vifor Pharma, INC. | $18.49 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.80 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.78 | 2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $16.09 | 2022 | |
| Daiichi Sankyo INC. | $14.48 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $14.24 | 2023 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Alva Valdes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.